EIF2AK3 and Alzheimer disease: Later, this was supplemented with immunohistochemistry data showing increased phosphorylation (activation) of UPR markers, including elevated levels of phosphorylated-PERK (p-PERK), p-eIF2α and p-IRE1 in the hippocampus of AD patients, as compared to non-demented controls [121,122].